Why the Bausch Health (BHC) Stock Price Fell 18.1% in February

The coronavirus negatively impacts Bausch Health stock price as revenue guidance disappoints and investors flock to safety.

| More on:
Financial technology concept.

Image source: Getty Images

Bausch Health Companies Inc. (TSX:BHC)(NYSE:BHC) stock price declined significantly in February as markets sold off. With this, Bausch Health stock price is now back to trading at 2018 levels, erasing all of its recent gains. So why did the stock sell off so sharply in February — and what should we do about it?

While there are a few specific reasons for this fall, I will sum it up in one line. Fearful investor sentiment had investors running for safety in February. For reasons I will discuss here, Bausch Health is not the stock to turn to for that.

Bausch Health stock price falls on disappointing results and guidance

In February, Bausch Health reported 2019 results that were mixed. Results out of Salix were the clear highlight. Let’s recall that Salix focuses on gastroenterology. The commitment is to “the prevention and treatment of gastrointestinal diseases and disorders.”

In the fourth quarter, this segment saw revenue increase more than 20%. This increase was once again driven by Xifaxan, the company’s top drug.

On the flip side, higher spending drove EBITDA margins lower and guidance was weak. The biggest issue for investors was the guidance, which calls for flat to marginal growth in 2020.

These disappointing numbers are certainly causing us to question management’s long-term guidance. Management’s target of 5% to 8% EBITDA growth between 2019 and 2022 appears less achievable now.

Bausch Health stock falls on coronavirus fears

For Bausch Health, the coronavirus is having have two major impacts. The first is the impact on revenue, which would result from a disruption in supply chains. This has been quantified to some extent by management. In their 2020 outlook, management expects revenue of $8.65 to $8.85 billion.

This includes a $50 million hit due to the coronavirus. The revenue guidance represents an expected growth rate of between 0.6% and 2.9%. Clearly, this is unimpressive.

Although a setback, it follows a period of revenue declines in the not too distant past, so at least we still have growth.

The second impact of the coronavirus is on the debt markets. Given its substantial debt burden, Bausch Health is in the process of refinancing existing loans. Anything the company can do to reduce the burden is a positive. But as the coronavirus spreads, fears are mounting.

As a result, investors are flocking to safety. As we know, corporate bonds of highly levered companies are not safe. Bausch is having difficulty refinancing existing loans on more favourable terms in this environment.

Foolish final thoughts

Bausch is Canada’s biggest healthcare stock and as such, it can’t be ignored. As a result of its size and investment in research, Bausch has a goldmine of products and competencies. The company’s biggest concerns are its debt levels, competition from generic drugs, and future growth possibilities.

As I have discussed in this article, Bausch is facing a difficult period. Despite this, management remains of the view that much of the growth will come in the 2021/2022 period.

Regardless, investors are nervous. Stagnating growth and heavy debt loads make Bausch Health stock a risky one.

In closing, I would like to remind Foolish investors of our belief in holding great businesses for the long term. While this belief remains intact, short-term stock price movements often create opportunities to create wealth.

We therefore need to blend this long-term focus with an eye for short-term stock mispricings. Only then can we use both strategies in harmony, and our quest for financial freedom can be fulfilled.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Karen Thomas has no position in any of the stocks mentioned. Tom Gardner owns shares of Bausch Health Companies. The Motley Fool owns shares of and recommends Bausch Health Companies.

More on Investing

Gold bars
Metals and Mining Stocks

Here’s a Precious Metals Stock With Less Risk

Wheaton is well positioned to form a small part of a much

Read more »

Natural gas prices are rising, making energy companies a good investment.
Energy Stocks

Bonterra Energy Stock Has Doubled: Is There More Upside in 2022?

It's been one of the best-performing TSX small-cap energy stocks in 2022, yet shares are cheap today.

Read more »

Early retirement handwritten in a note
Stocks for Beginners

How This Stock Market Selloff Can Help You Retire Early

The ongoing market crash can massively enhance your potential long-term profits to let you plan your early retirement.

Read more »

Question marks in a pile
Tech Stocks

Should You Finally Buy BlackBerry (TSX:BB)?

Is it time to finally buy BlackBerry?

Read more »

Community homes
Dividend Stocks

Canada’s House Prices Cool: 1 REIT to Buy the Dip

Canada’s house prices are cooling. Should you be concerned about falling house prices or use the dip to buy a…

Read more »

grow dividends
Tech Stocks

3 Top TSX Growth Stocks to Buy for Less Than $10

These high-growth TSX stocks are trading less than $10 and have strong potential to beat the broader markets in the…

Read more »

Top view of mixed race business team sitting at the table at loft office and working. Woman manager brings the document
Bank Stocks

Top 2 Stocks for Beginners in 2022

Bank stocks like Bank of Montreal (TSX:BMO)(NYSE:BMO) are top picks for 2022.

Read more »

protect, safe, trust
Dividend Stocks

Market Selloff: 2 Safe-Haven Dividend Stocks to Limit Your Losses

Instead of worrying about the ongoing market selloff, investors should act now and add some safe dividend stocks to their…

Read more »